Opendata, web and dolomites

NOVITREP

Novel viral therapy through targeting DNA repair

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NOVITREP project word cloud

Explore the words cloud of the NOVITREP project. It provides you a very rough idea of what is the project "NOVITREP" about.

health    agency    drug    ip    human    potently    therapy    market    outbreaks    threatening    hemorrhagic    investigation    reduce    cycle    company    host    prevent    fever    western    relationship    cchfv    therapies    cell    suggesting    ongoing    proteins    repair    revealed    cells    tool    power    plan    anti    diseases    oxidative    made    therapeutic    internationally    causal    action    explore    grant    born    income    genecadd    ebov    optimize    prevented    resistance    exists    constant    infected    crimean    zikv    treatments    congo    surprise    replication    natural    erc    therapeutics    pathogenic    business    antiviral    epidemics    life    individuals    outbreak    ebola    foundation    secure    damage    battle    global    microcephaly    networks    newly    virus    disturbs    demonstrating    rna    strategy    inhibitors    dna    cancer    genetic    acquired    pose    discover    lesions    world    zika    sweden    infectious    babies    mechanism    viruses    viral    potent    causing    perform    proof    zoonotic    public   

Project "NOVITREP" data sheet

The following table provides information about the project.

Coordinator
KAROLINSKA INSTITUTET 

Organization address
address: Nobels Vag 5
city: STOCKHOLM
postcode: 17177
website: www.ki.se

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-07-01   to  2018-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    KAROLINSKA INSTITUTET SE (STOCKHOLM) coordinator 139˙162.00
2    KAROLINSKA INSTITUTET INNOVATIONS AB SE (SOLNA) participant 10˙837.00

Map

 Project objective

Natural epidemics and outbreaks of emerging infectious diseases are a growing problem internationally. RNA viruses remain under constant attention due to the recent Zika virus (ZIKV) outbreak with potential causal relationship with microcephaly of newly born babies and Ebola virus (EBOV) and Crimean-Congo hemorrhagic fever virus (CCHFV) causing life threatening hemorrhagic fever, demonstrating how zoonotic viruses pose a major global health concern. There is an ongoing need to discover novel therapies to battle these pathogenic viruses given that no specific therapy exists. Developing new antiviral treatments by targeting host cell proteins needed in the viral life cycle is an emerging strategy to improve therapeutic power and reduce acquired drug resistance.

Based on the results from the ERC grant Genetic Networks as a tool for anti-Cancer Drug Development (GENECADD), we have developed potent inhibitors to DNA repair proteins that disturbs repair of oxidative DNA lesions. To our surprise, we observed, in collaboration with Public Health Agency of Sweden, that these inhibitors potently prevent ZIKV, EBOV and CCHFV viral replication in human cells, suggesting that these inhibitors may be used as antiviral therapeutics. Further investigation into the possible mechanism of action revealed that our inhibitors prevented the repair of oxidative damage to RNA.

Here, the overall aim is to (1) further develop and optimize our inhibitors as a novel antiviral target and demonstrate proof of concept, (2) explore and secure IP (3) develop a business plan and (4) perform a market analysis. The overall goal is to develop general antiviral treatments made available to virus-infected individuals through a public foundation in low-income areas or through a company in the Western world.

 Publications

year authors and title journal last update
List of publications.
2018 Torkild Visnes, Armando Cázares-Körner, Wenjing Hao, Olov Wallner, Geoffrey Masuyer, Olga Loseva, Oliver Mortusewicz, Elisée Wiita, Antonio Sarno, Aleksandr Manoilov, Juan Astorga-Wells, Ann-Sofie Jemth, Lang Pan, Kumar Sanjiv, Stella Karsten, Camilla Gokturk, Maurice Grube, Evert J. Homan, Bishoy M. F. Hanna, Cynthia B. J. Paulin, Therese Pham, Azita Rasti, Ulrika Warpman Berglund, Catharina von Nicolai, Carlos Benitez-Buelga, Tobias Koolmeister, Dag Ivanic, Petar Iliev, Martin Scobie, Hans E. Krokan, Pawel Baranczewski, Per Artursson, Mikael Altun, Annika Jenmalm Jensen, Christina Kalderén, Xueqing Ba, Roman A. Zubarev, Pål Stenmark, Istvan Boldogh, Thomas Helleday
Small-molecule inhibitor of OGG1 suppresses proinflammatory gene expression and inflammation
published pages: 834-839, ISSN: 0036-8075, DOI: 10.1126/science.aar8048
Science 362/6416 2019-09-04

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NOVITREP" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NOVITREP" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

LO-KMOF (2019)

Vapour-deposited metal-organic frameworks as high-performance gap-filling dielectrics for nanoelectronics

Read More  

PLAT_ACE (2019)

A new platform technology for the on-demand access to large acenes

Read More  

TRUST (2018)

Truth and Semantics

Read More